Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia

Abstract

The success of tyrosine kinase inhibitors in treating chronic myeloid leukemia highlights the potential of targeting oncogenic kinases with small molecules. By using drug activity profiles and individual patient genotypes, one can guide personalized therapy selection for patients with resistance.